Humacyte reports Q4 EPS (13c), consensus (14c)

Reports Q4 revenue $467,000, consensus $1.35M. “We continued to execute our U.S. market launch of Symvess, and in parallel have taken major steps to expand the commercialization of the product to international markets,” said Laura Niklason, founder and CEO of Humacyte (HUMA). “Awareness and usage among surgeons continue to grow, with product sales totaling $0.4 million for fourth quarter and $1.4 million for the full year. We are pleased that the U.S. Department of Defense has dedicated funding for evaluation and incorporation of new biologic vascular repair technologies, and we look forward to working with leaders in our military and the Pentagon to ensure that American service personnel will have access to Symvess. International interest in Symvess is highlighted by a $1.475 million purchase commitment to enable the education of surgeons and the evaluation of Symvess by hospitals within the Kingdom of Saudi Arabia. We have also submitted a Marketing Authorization Application with the Ministry of Health of the State of Israel for Symvess for arterial trauma repair.”